Xenon Pharmaceuticals Inc (XENE) - News Archive

In a significant move highlighting its commitment to innovation and growth, Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a biopharmaceutical company deeply rooted in neuroscience, announced today the issuance of equity in...

Long-Term Data from X-TOLE OLE Study Highlights Azetukalner s Efficacy and Safety in Seizure Management at AES 2024At the recent annual meeting of the American Epilepsy Society (AES) 2024, Xenon Pharmaceuticals captured...

Xenon Pharmaceuticals Showcases Promising Advances in MDD and Epilepsy Treatments at Major Industry ConferencesXenon Pharmaceuticals Inc. (Nasdaq:XENE), a leading neurology-focused biopharmaceutical company, has recentl...

Xenon Pharmaceuticals Achieves Solid Financial Performance as Its Epilepsy Program AdvancesXenon Pharmaceuticals, a leading biopharmaceutical company, recently released its financial results for the fourth quarter and f...

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)VANCOUVER, British Columbia, Dec. 02, 2023 - Xenon Pharmaceuticals Inc. (Nasdaq:XENE...

On November 29, 2023, Xenon Pharmaceuticals Inc., a leading biopharmaceutical company focusing on neurology, made a significant announcement regarding its plans for a new public offering. The company has commenced an un...

Xenon Pharmaceuticals, a leading clinical-stage biopharmaceutical company, announced the awaited topline results from their Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the efficacy and safety of XEN1...